行情

ACER

ACER

Acer医疗
NASDAQ

实时行情|Nasdaq Last Sale

3.500
-0.130
-3.58%
盘后: 3.430 -0.07 -2.00% 17:19 07/10 EDT
开盘
3.680
昨收
3.630
最高
3.690
最低
3.330
成交量
20.94万
成交额
--
52周最高
7.25
52周最低
1.080
市值
3,587.21万
市盈率(TTM)
-1.3383
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ACER价格均价为10.00,最高价位10.00,最低价为10.00。

EPS

ACER 新闻

更多
Acer Therapeutics rallies on encouraging ACER-001 data
Seeking Alpha - Article · 3天前
CLNE, NTES among premarket gainers
Seeking Alpha - Article · 3天前
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 3天前
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study
GlobeNewswire · 3天前
Acer Therapeutics Announces Administration Of ACER-001 In A Fasted State Increased Systemic Exposure Of Phenylbutyrate In Healthy Volunteer Food Effect Study
Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to current
Benzinga · 3天前
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Acer Therapeutics Inc. Investors (ACER)
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. ("Acer" or the "Company") (NASDAQ: ACER) concerning whether the board breached its fiduciary duties to shareholders.
Business Wire · 06/24 17:53
Ultragenyx Pharmaceutical: Near-Term Catalysts Offer Best Of Both Worlds
Seeking Alpha - Article · 06/16 15:00
Is Acer Therapeutics Inc. (ACER) A Good Stock To Buy?
Insider Monkey · 05/29 17:44

所属板块

生物技术和医学研究
-0.39%
制药与医学研究
-0.32%

热门股票

代码
价格
涨跌幅

ACER 简况

Acer Therapeutics Inc(原名:Opexa Therapeutics Inc)是一家制药公司。该公司从事获、开发并试图商业化用于患有严重罕见疾病且有严重未满足医疗需求的患者的疗法。其临床后期产品包括Edsivo(celiprolol)和ACER-001。该公司在美国正在开发治疗血管性埃勒斯-当洛斯综合征(vEDS)的产品Edsivo。其正在开发ACER-001,这是一种用于治疗枫糖尿症(MSUD)的药物治疗选择。ACER-001是使用微囊化工艺开发的苯基丁酸钠(NaPB)的速释制剂。该公司也正在开发治疗尿素循环障碍的ACER-001。
展开

微牛提供Acer Therapeutics Inc(NASDAQ-ACER)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ACER股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ACER股票基本功能。